Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Nucleotides, viral vectors and their applications and RNAi pharmaceutical preparations

A technology of viral vectors and pharmaceutical preparations, applied in the field of biomedicine, can solve problems such as affecting the efficiency of RNAi and the amount of shRNA

Active Publication Date: 2022-07-15
WUHAN NEUROPHTH BIOTECHNOLOGY LTD CO
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] In mammalian cells, RNAi can be induced by directly introduced siRNA, or can be induced by expressing shRNA (hairpin RNA) through a hairpin structure of a DNA vector such as a plasmid, a viral vector, or a PCR product. For the latter method, it is induced by DNA carrier-mediated RNAi reaction can overcome the problem that siRNA cannot replicate in mammalian cells, but the amount of shRNA it produces is affected by different promoters, which in turn affects RNAi efficiency

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nucleotides, viral vectors and their applications and RNAi pharmaceutical preparations
  • Nucleotides, viral vectors and their applications and RNAi pharmaceutical preparations
  • Nucleotides, viral vectors and their applications and RNAi pharmaceutical preparations

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] Example 1 Construction of shRNA vectors expressed by different promoters

[0045] 1. Promoter fragment digestion

[0046] After the gene sequences of SEQ ID NOs: 1-6 were synthesized by the gene, they were digested with endonuclease respectively, and the enzyme digestion system was as follows:

[0047]

[0048] The pAAV2 plasmid was digested with the same method, and the target band was recovered after 1 h of reaction at 37°C.

[0049] 2. Construction of recombinant vector

[0050] Take the fragment and the vector cut by the above-mentioned enzyme, respectively, and connect them. The connection system is as follows:

[0051]

[0052] After the ligation system was reacted at 25°C for 10 min, the ligation product was taken to transform stbl3 competent cells. Mix well according to the following reaction system, place on ice for 20 min, place at room temperature for 10 min, add 500 μL of anti-anti-LB at 37°C, incubate at 200 rpm for 40 min, then centrifuge at 5000 ...

Embodiment 2

[0079] Example 2 Screening of efficient RNAi drugs by luciferase reporter system

[0080] 1. Culture of mammalian cells (adherent)

[0081] 1. Cell recovery

[0082] 1) Prepare warm water at 37°C-38°C in advance, take out the cells to be resuscitated from the liquid nitrogen tank, fix them with ophthalmic surgical forceps, and quickly place them in water to ensure that the cryovials are completely immersed in water, so that they are evenly heated until frozen. The cells in the deposit tube are completely thawed;

[0083] 2) Disinfect the cryopreservation tube with alcohol;

[0084] 3) Pipette 5mL of cell culture-based T25 cell culture flask in advance with a pipette, and then use a new pipette to transfer the thawed cells into the cell flask and gently pipette again;

[0085] 4) Cover the cell flask and place the cell flask in a cell incubator at 37°C, 5% CO 2 static culture;

[0086] 5) After about 6-8 hours (depending on different cells), replace with fresh medium to el...

Embodiment 3

[0109] Example 3 RNAi drug treatment inhibits mutation-specific COL8A2 gene expression

[0110] 1. 293 cell transfection:

[0111] The method is the same as before.

[0112] 2. Detection of COL8A2 RNA level by reverse transcription fluorescent quantitative PCR

[0113] 1. The reverse transcription reaction system is as follows:

[0114]

[0115] Reverse transcription reaction conditions: 37°C for 1 h, 75°C for 10 min.

[0116] 2. Real-time reaction system

[0117] 1) Detection primers and internal reference primers for the target gene

[0118] COL8A2: 5'-GGCGGGCTATGCCCCAGTGAAGTAC-3'(sense)

[0119] 5’-CTGGCTTTCCCATGCCTGGTTTTCC-3’(antisense)

[0120] GAPDH: 5'-GGAAGGTGAAGGTCGGAGTCAACGG-3'(sense)

[0121] 5’-CTCGCTCCTGGAAGATGGTGATGGG-3’(antisense)

[0122] 2) Reaction system

[0123]

[0124] 3) Reaction procedure:

[0125]

[0126] 3. AAV infected 293 cells

[0127] Recombinant virus AAV-shRNA control, AAV-shRNA drug with MOI=1×10 4 The multiplicity of infect...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the technical field of biomedicine, in particular to nucleotides, viral vectors and their applications and RNAi pharmaceutical preparations. The nucleotide is selected from one of the following nucleic acid sequences: the nucleic acid sequence is one of SEQ ID NO: 3 or SEQ ID NO: 4; at 80% of the nucleic acid sequence. The promoter-optimized RNAi medicine of the invention has the effect of treating and preventing corneal dystrophy caused by the Q455K mutation of COL8A2 gene.

Description

technical field [0001] The present invention relates to the technical field of biomedicine, in particular to nucleotides, viral vectors and their applications and RNAi pharmaceutical preparations. Background technique [0002] Corneal dystrophy (CD) is a hereditary ophthalmological disease. The age of onset is mostly over 20 years old. The cells in the patient's corneal tissue undergo progressive changes in their function and structure due to gene mutation, and abnormal substances in the corneal tissue occur. Progressive deposition is its histopathological feature. According to the level of corneal involvement of the corneal dystrophy, CD is classified into four categories: corneal epithelial and subepithelial dystrophy, corneal preelastic dystrophy, corneal stromal dystrophy, and corneal Descemet and corneal endothelial dystrophy. Among them, corneal endothelial cell dystrophy includes FECD (Fuchs corneal endothelial dystrophy, Fuchs endothelial corneal dystrophy, FECD), P...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N15/113C12N15/864A61K31/7105A61P27/02
CPCC12N15/113C12N15/86A61P27/02C12N2310/14C12N2310/531C12N2750/14143C12N2800/107C12N2320/32
Inventor 李斌任盛
Owner WUHAN NEUROPHTH BIOTECHNOLOGY LTD CO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com